Recent News

• 04.01.2025 - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
• 03.31.2025 - Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
• 03.31.2025 - Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
• 03.28.2025 - Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.12.2025 - Leerink Partners Global Biopharma Conference
• 03.03.2025 - Connect Biopharma to Present at Two Upcoming Investor Conferences
• 12.03.2024 - December 3, 2024 12:30 PM EST - December 3, 2024 12:55 PM EST : NobleCon20
• 09.19.2024 - Cantor Fitzgerald Global Healthcare Conference 2024
• 09.10.2024 - Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

Recent Filings

• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.28.2025 - EX-99.1 EX-99.1
• 12.23.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.06.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.05.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.02.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]